Radiolabeled somatostatin analogs for cancer treatment. Review

«Radiation and Risk», 2022, vol. 31, No. 2, pp.76-96

DOI: 10.21870/0131-3878-2022-31-2-76-96

Authors

Tishchenko V.K. – Lead. Researcher, D. Sc., Biol.
Petriev V.M. – Head of Lab., D. Sc., Biol., Prof. of MEPhI. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel.: (484) 399-71-00; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Krylov V.V. – Head of Dep., MD
Vlasova O.P. – Lead. Researcher, C. Sc., Biol.
Ivanov S.A. – Director, MD, Prof. of RAS. A. Tsyb MRRC.
Shegai P.V. – Deputy General Director, C. Sc., Med.
Kaprin A.D. – General Director, Academician of RAS, MD, Prof. NMRRC.
1 A. Tsyb MRRC, Obninsk
2 National Research Nuclear University MEPhI, Moscow
3 NMRRC, Moscow

Abstract

Currently, a specific action on tumor cells with minimal toxicity to healthy tissues is the main requirement for radionuclide therapy of cancer. The molecular target of selective antitumor therapy is determined by somatostatin receptors (SSTR) overexpression in various tumors and its metastases. Natural somatostatin cannot be used as a vector molecule for radionuclide delivery due to its short half-life in blood (1-3 min). Synthetic peptide somatostatin analogs labeled with therapeutic radionuclides (radiopeptides) also have high affinity to SSTR and better pharmacokinetics compared to somatostatin and therefore they are of great interest for targeted cancer therapy, also called peptide-receptor radionuclide therapy (PRRT). The data about the most important to date somatostatin analogs labeled with 111In, 90Y, 177Lu radionuclides for therapy of tumors overexpressing SSTR is presented. The results of treatment efficacy and toxicity profile of PRRT, which is administered with various generations of targeting SSTR radiopharmaceuticals, including the randomized controlled trial NETTER-1, is reviewed. In addition, some strategies for optimization of PRRT such as tandem therapy, intra-arterial administration of radiopharmaceuticals, their modification for better pharmacokinetic properties, and the development of new compounds containing alpha-emitting radionuclides or SSTR antagonist analogs are discussed.

Key words
somatostatin analogs, radiopeptides, peptide-receptor radionuclide therapy, somatostatin receptors, octreotide derivatives, radiopharmaceutical, DOTATOC, DOTATATE, neuroendocrine tumors.

References

1. Global Cancer Observatory. Available at: https://gco.iarc.fr/ (Accessed 08.02.2022).

2. Reubi J.C., Laissue J., Krenning E., Lamberts S.W. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. Mol. Biol., 1992, vol. 43, no. 1-3, pp. 27-35.

3. Okarvi S.M. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat. Rev., 2008, vol. 34, no. 1, pp. 13-26.

4. Eychenne R., Bouvry C., Bourgeois M., Loyer P., Benoist E., Lepareur N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules, 2020, vol. 25, no. 17, pp. 4012.

5. Reubi J.C., Waser B., Schaer J.C., Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med., 2001, vol. 28, no. 7, pp. 836-846.

6. Volante M., Rosas R., Allìa E., Granata R., Baragli A., Muccioli G., Papotti M. Somatostatin, cortistatin and their receptors in tumours. Mol. Cell Endocrinol., 2008, vol. 286, no. 1-2, pp. 219-229.

7. Pauwels E., Cleeren F., Bormans G., Deroose C.M. Somatostatin receptor PET ligands – the next genera-tion for clinical practice. Am. J. Nucl. Med. Mol. Imaging, 2018, vol. 8, no. 5. pp. 311-331.

8. Bidakhvidi A.N., Goffin K., Dekervel J., Baete K., Nackaerts K., Clement P., van Cutsem E., Verslype C., Deroose C.M. Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies. Cancers (Basel), 2022, vol. 14, no. 1, pp. 129.

9. Krenning E.P., Valkema R., Kooji P.P., Breeman W.A., Bakker W.H., de Herder W.W., van Eijck C.H., Kwekkeboom D.J., de Jong M., Pauwels S. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital. J. Gastroenterol. Hepatol., 1999, vol. 3, no. S2, pp. S219-S223.

10. Valkema R., de Jong M., Bakker W.H., Breeman W.A., Kooij P.P., Lugtenburg P.J., de Jong F.H., Christiansen A., Kam B.L., de Herder W.W., Stridsberg M., Lindemans J., Ensing G., Krenning E.P. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin. Nucl. Med., 2002, vol. 32, no. 2, pp. 110-122.

11. Delpassand E.S., Sims-Mourtada J., Saso H., Azhdarinia A., Ashoori F., Torabi F., Espenan G, Moore W.H., Woltering E., Anthony L. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother. Radiopharm., 2008, vol. 23, no. 3, pp. 292-300.

12. Waldherr C., Pless M., Maecke H.R., Haldemann A., Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol., 2001, vol. 12, no. 7. pp. 941-945.

13. Waldherr C., Pless M., Maecke H.R., Schumacher T., Crazzolara A., Nitzsche E.U., Haldemann A., Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J. Nucl. Med., 2002, vol. 43, no. 5, pp. 610-616.

14. Krenning E.P., Kwekkeboom D.J., Valkema R., Pauwels S., Kvols L.K., de Jong M. Peptide receptor radionuclide therapy. Ann. N.Y. Acad. Sci., 2004, vol. 1014, no. 1, pp. 234-245.

15. Virgolini I., Traub T., Novotny C., Leimer M., Füger B., Li SR., Patri P., Pangerl T., Angelberger P., Raderer M., Burggasser G., Andreae F., Kurtaran A., Dudczak R. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr. Pharm. Des., 2002, vol. 8, no. 20, pp. 1781-1807.

16. Virgolini I., Britton K., Buscombe J., Moncayo R., Paganelli G., Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med., 2002, vol. 32, no. 2, pp. 148-155.

17. Esser J.P., Krenning E.P., Teunissen J.J., Kooij P.P., van Gameren A.L., Bakker W.H., Kwekkeboom D.J. Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: Which peptide is preferable for PRRT? Eur. J. Nucl. Med. Mol. Imaging, 2006, vol. 33, no. 11, pp. 1346-1351.

18. Strosberg J., El-Haddad G., Wolin E., Hendifar A., Yao J., Chasen B., Mittra E., Kunz P.L., Kulke M.H., Jacene H., Bushnell D., O’Dorisio T.M., Baum R.P., Kulkarni H.R., Caplin M., Lebtahi R., Hobday Y., Delpassand E., van Cutsem E., Benson A., Srirajaskanthan R., Pavel M., Mora J., Berlin J., Grande E., Reed N., Seregni E., Ӧberg K., Sierra M.L., Santoro P., Thevenet T., Erion J.L., Ruszniewski P., Kwekkeboom D., Krenning E., NETTER-1 Trial investigators. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med., 2017, vol. 376, no. 2, pp. 125-135.

19. Strosberg J., Caplin M.E., Kunz P.L., Ruszniewski P.B., Bodei L., Hendifar A., Mittra E., Wolin E.M., Yao J.C., Pavel M.E., Grande E., van Cutsem E., Seregni E., Duarte H., Gericke G., Bartalotta A., Mariani M.F., Demange A., Mutevelic S., Krenning E.P., NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol., 2021, vol. 22, no. 12, pp. 1752-1763.

20. Hennrich U., Kopka K. Lutathera®: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel), 2019, vol. 12, no. 3, pp. 114.

21. Vegt E., de Jong M., Wetzels J.F.M., Masereeuw R., Melis M., Oyen W.J.G., Gotthardt M., Boerman O.C. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J. Nucl. Med., 2010, vol. 51, no. 7, pp. 1049-1058.

22. Bodei L., Cremonesi M., Zoboli S., Grana C., Bartolomei M., Rocca P., Caracciolo M, Mäcke H.R., Chinol M., Paganelli G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur. J. Nucl. Med. Mol. Imaging, 2003, vol. 30, no. 2, pp. 207-216.

23. Brabander T., van der Zwan W.A., Teunissen J.J.M., Kam B.L.R., Feelders R.A., de Herder W.W., van Eijck C.H.J., Franssen G.J.H., Krenning E.P., Kwekkeboom D.J. Long-term efficacy, survival, and safety of [177Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendo-crine tumors. Clin. Cancer Res., 2017, vol. 23, no. 16, pp. 4617-4624.

24. Goncalves I., Burbury K., Michael M., Iravani A., Ravi Kumar A.S., Akhurst T., Tiong I.S., Blombery P., Hofman M.S., Westerman D., Hicks R.J., Kong G. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Eur. J. Nucl. Med. Mol. Imaging, 2019, vol. 46, no. 9, pp. 1902-1910.

25. Chantadisai M., Kulkarni H.R., Baum R.P. Therapy-related myeloid neoplasm after peptide receptor radio-nuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival. Eur. J. Nucl. Med. Mol. Imaging, 2021, vol. 48, no. 5, pp. 1390-1398.

26. Bergsma H., van Lom K., Raaijmakers M.H.G.P., Konijnenberg M., Kam L.R., Teunissen J.J.M., de Herder W.W., Krenning E.P., Kwekkeboom D.J. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med., 2018, vol. 59, no. 3, pp. 452-458.

27. de Jong M., Breeman W.A.P., Valkema R., Bernard B.F., Krenning E.P. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J. Nucl. Med., 2005, vol. 46, no. S1, pp. 13S-17S.

28. Villard L., Romer A., Marincek N., Brunner P., Koller M.T., Schindler C., Ng Q.K.T., Mäcke H.R., Müller-Brand J., Rochlitz C., Briel M., Walter M.A. Cohort study of somatostatin-based radiopeptide therapy with (90)Y-DOTA-TOC versus (90)Y-DOTA-TOC plus (177)Lu-DOTA-TOC in neuroendocrine cancers. J. Clin. Oncol., 2012, vol. 30, no. 10, pp. 1100-1106.

29. Kunikowska J., Królicki L., Hubalewska-Dydejczyk A., Mikołajczak R., Sowa-Staszczak A., Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging, 2011, vol. 38, no. 10, pp. 1788-1797.

30. Parghane R.V., Mitra A., Bannore T.U., Rakshit S., Banerjee S., Basu S. Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, 90Y-DOTATATE post-PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects. World J. Nucl. Med., 2021, vol. 20, no. 1, pp. 73-81.

31. Baum R.P., Kulkarni H.R., Singh A., Kaemmerer D., Mueller D., Prasad V., Hommann M., Robiller F.C., Niepsch K., Franz H., Jochems A., Lambin P., Hörsch D. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget, 2018, vol. 9, no. 24, pp. 16932-16950.

32. Singh A., Zhang J., Kulkarni H., Baum R. Intra-arterial PRRT of sstr-expressing tumors in patients with hepatic only versus extrahepatic tumor: efficacy and safety evaluation. J. Nucl. Med., 2019, vol. 60, no. S1, pp. 625.

33. Kolasińska-Ćwikła A., Nowicki M.L., Sankowski A.J., Pałucki J.M., Buscombe J.R., Glinka L., Ćwikła J.B. Radiological and clinical efficacy of intra-arterial 90Y-DOTATATE in patients with unresectable, progres-sive, liver dominant neuroendocrine neoplasms. J. Clin. Med., 2021, vol. 10, no. 8, pp. 1794.

34. Thakral P., Sen I., Das S.S., Manda D., Cb V., Malik D. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br. J. Radiol., 2021, vol. 94, no. 1126, pp. 20210403.

35. Tian R., Jacobson O., Niu G., Kiesewetter D.O., Wang Z., Zhu G., Ma Y., Liu G., Chen X. Evans blue attachment enhances somatostatin receptor subtype-2 imaging and radiotherapy. Theranostics, 2018, vol. 8, no. 3, pp. 735-745.

36. Zhang J., Wang H., Jacobson O., Cheng Y., Niu G., Li F., Bai C., Zhu Z., Chen X. Safety, pharmacokinetics, and dosimetry of a long-acting radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors. J. Nucl. Med., 2018, vol. 59, no. 11, pp. 1699-1705.

37. Liu Q., Zang J., Sui H., Ren J., Guo H., Wang H., Wang R., Jacobson O., Zhang J., Cheng Y., Zhu Z., Chen X. Peptide receptor radionuclide therapy of late-stage neuroendocrine tumor patients with multiple cycles of 177Lu-DOTA-EB-TATE. J. Nucl. Med., 2021, vol. 62, no. 3, pp. 386-392.

38. Zamora P.O., Gulhke S., Bender H., Diekmann D., Rhodes B.A., Birsack H.J., Knapp Jr. F.F. Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int. J. Cancer, 1996, vol. 65, no. 2, pp. 214-220.

39. Molina-Trinidad E.M., Arteaga de Murphy C., Ferro-Flores G., Murphy-Stack E., Jung-Cook H. Radio-pharmacokinetic and dosimetric parameters of 188Re-lanreotide in athymic mice with induced human cancer tumors. Int. J. Pharm., 2006, vol. 310, no. 1-2, pp. 125-130.

40. Nelson C.A., Aure M.T., Adams C.T., Zinn K.R. The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J. Nucl. Med., 2014, vol. 55, no. 12, pp. 2020-2025.

41. Edelman M.J., Clamon G., Kahn D., Magram M., Lister-James J., Line B.R. Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog. J. Thorac. Oncol., 2009, vol. 4, no. 12, pp. 1550-1554.

42. Baum P., Singh A., Kulkarni H., Bernhardt P., Ryden T., Schuchardt C., Gracheva N., Grundler P.V., Köster U., Müller D., Pröhl M., Zeevaart J.R., Schibli R., van de Meulen N.P. First-in-humans application of 161Tb: a feasibility study using 161Tb-DOTATOC. J. Nucl. Med., 2021, vol. 62, no. 10, pp. 1391-1397.

43. Loveless C.S., Radford L.L., Ferran S.J., Queern S., Shepherd M.R., Lapi S.E. Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc. EJNMMI Res., 2019, vol. 9, no. 1, pp. 42.

44. King A.P., Lin F.I., Escorcia F.E. Why bother with alpha particles? Eur. J. Nucl. Med. Mol. Imaging, 2021, vol. 49, no. 1, pp. 7-17.

45. Norenberg J.P., Krenning B.J., Konings I.R., Kusewitt D.F., Nayak T.K., Anderson T.L., de Jong M., Garmestani K., Brechbiel M.W., Kvols L.K. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin. Cancer Res., 2006, vol. 12, pp. 897-903.

46. Miederer M., Henriksen G., Alke A., Mossbrugger I., Quintanila-Martinez L., Senekowitsch-Schmidtke R., Essler M. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin. Cancer Res., 2008, vol. 14, no. 11, pp. 3555-3561.

47. Rozgaja Stallons T.A., Saidi A., Tworowska I., Delpassand E.S., Torgue J.J. Preclinical investigation of 212Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model. Mol. Cancer. Ther., 2019, vol. 18, no. 5, pp. 1012-1021.

48. Kratochwil C., Bruchertseifer F., Giesel F.L. Ac-225-DOTATOC – dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging, 2015, vol. 42, no. S1, pp. S36.

49. Zhang J., Kulkarni H.R., Baum R.P. 225Ac-DOTATOC-targeted somatostatin receptor -therapy in a patient with metastatic neuroendocrine tumor of the thymus, refractory to -radiation. Clin. Nucl. Med., 2021, vol. 46, no. 12, pp. 1030-1031.

50. Kratochwil C., Apostolidis L., Rathke H., Apostolidis C., Bicu F., Bruchertseifer F., Choyke P.L., Haberkorn U., Giesel F.L., Morgenstern A. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur. J. Nucl. Med. Mol. Imaging, 2021, vol. 49, no. 1, pp. 54-63.

51. Ballal S., Yadav M.P., Bal C., Sahoo R.K., Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur. J. Nucl. Med. Mol. Imaging, 2020, vol. 47, no. 4, pp. 934-946.

52. Delpassand E.S., Tworowska I., Esfandiari R., Torgue J., Hurt J., Shafile A., Nunez R. Targeted alpha-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial. J. Nucl. Med., 2022, vol. 63, no. 3, pp. jnumed.121.263230.

53. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J., Mäcke H.R., Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. USA, 2006, vol. 103, no. 44, pp. 16436-16441.

54. Cescato R., Waser B., Fani M., Reubi J.C. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J. Nucl. Med., 2011, vol. 52, no. 12, pp. 1886-1890.

55. Wang X. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging, 2012, vol. 39, no. 12, pp. 1876-1885.

56. Nicolas G.P., Mansi R., McDougall L., Kaufmann J., Bouterfa H., Wild D., Fani M. Biodistribution, pharma-cokinetics, and dosimetry of 177Lu-, 90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in compar-ison to the agonist 177Lu-DOTATATE: the mass effect. J. Nucl. Med., 2017, vol. 58, no. 9, pp. 1435-1441.

57. Dalm S.U., Nonnekens J., Doeswijk G.N., de Blois E., van Gent D.C., Konijnenberg M.W., de Jong M. Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J. Nucl. Med., 2016, vol. 57, no. 2, pp. 260-265.

58. Wild D., Fani M., Fischer R., Del Pozzo L., Kaul F., Krebs S., Fischer R., Rivier J., Reubi J.C., Maecke H.R., Weber W.A. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionu-clide therapy: a pilot study. J. Nucl. Med., 2014, vol. 55, no. 8, pp. 1248-1252.

59. Reidy-Lagunes D., Pandit-Taskar N., O’Donoghue J.A., Krebs S., Staton K.D., Lyashchenko S.K., Lewis J.S., Raj N., Gönen M., Lohrmann C., Bodei L., Weber W.A. Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist 177Lu-satoreotide tetraxetan. Clin. Cancer Res., 2019, vol. 25, no. 23, pp. 6939-6947.

60. Schuchardt C., Kulkarni H., Singh A., Müller D., Fani M., Maecke H., Baum R. Peptide receptor radionu-clide therapy using somatostatin receptor antagonists: first results of biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC. J. Nucl. Med., 2019, vol. 60, no. S1, pp. 352.

61. Baum R.P., Zhang J., Schuchardt C., Müller D., Mäcke H. First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy. J. Nucl. Med., 2021, vol. 62, no. 11, pp. 1571-1581.

62. Borgna F., Haller S., Monné Rodriguez J.M., Ginj M., Grundler P.V., Zeevaart J.R., Köster U., Schibli R., van der Meulen N.P., Müller C. Combination of terbium-161 with somatostatin receptor antagonists – a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur. J. Nucl. Med. Mol. Imaging, 2022, vol. 49, no. 4, pp. 1113-1126.

63. Fani M, Nicolas G.P., Wild D. Somatostatin receptor antagonists for imaging and therapy. J. Nucl. Med., 2017, vol. 58, no. S2, pp. 61S-66S.

Full-text article (in Russian)